TABLE 1.
Comparisons of blood pressure, kidney GC activity, and cGMP levels among Npr1 genotypes treated with ATRA and NaBu
Measurement of systolic blood pressure, renal GC activity, and cGMP levels in ATRA- and NaBu-treated mice. Blood pressure was measured by a computerized tail-cuff method in Npr1 gene-targeted mice. Kidney GC activity and cGMP levels were quantitated by enzyme-linked immunosorbent assay as described in Materials and Methods. Values represent the mean ± S.E. of three independent experiments in triplicate.
| Treatments/Parameters |
Npr1 Genotype |
||
|---|---|---|---|
| 1-Copy | 2-Copy | 3-Copy | |
| Systolic blood pressure (mm Hg) | |||
| Vehicle | 128.2 ± 2.1### | 103.4 ± 1.8 | 94.7 ± 1.1# |
| ATRA | 114.6 ± 2.2** | 100.0 ± 1.9 | 92.8 ± 0.9 |
| NaBu | 119.2 ± 1.7* | 101.9 ± 3.8 | 92.4 ± 1.6 |
| ATRA + NaBu | 108.8 ± 3.1*** | 97.9 ± 1.3 | 88.43 ± 2.1 |
| GC activity (pmol cGMP/mg protein/30 min) | |||
| Vehicle | 24.8 ± 2.1## | 68.6 ± 3.3 | 116.2 ± 4.5# |
| ATRA | 40.7 ± 7.4* | 91.4 ± 3.5** | 145.7 ± 6.3* |
| NaBu | 31.8 ± 1.8* | 79.9 ± 8.8* | 133.3 ± 11.4* |
| ATRA + NaBu | 58.5 ± 2.5** | 106.1 ± 5.6** | 195.2 ± 7.5** |
| cGMP (pmol/mg protein) | |||
| Vehicle | 11.8 ± 0.9# | 34.3 ± 1.8 | 82.3 ± 6.8# |
| ATRA | 21.9 ± 1.3* | 57.4 ± 5.1** | 121.7 ± 10.1* |
| NaBu | 19.4 ± 0.7* | 46.5 ± 5.9* | 101.5 ± 5.3* |
| ATRA + NaBu | 36.3 ± 1.8** | 84.4 ± 7.6** | 160.2 ± 12.5** |
*
P < 0.05; **P < 0.01; ***P < 0.001 (vehicle-treated control versus drug-treated same gene copy number); #P < 0.05; ##P < 0.01; ###P < 0.001 (vehicle-treated 1- and 3-copy versus vehicle-treated 2-copy); n = 6 in each group.